| Ytd | -8.69% | |
| 1y | 1.00% |
| Open | 7.19 | Prev Close | 7.08 | Low | 6.97 | High | 7.28 | Mkt Cap | 193.84M |
| Vol | 155.60K | Avg Vol | 275.13K | EPS | -0.37 | P/E | N/A | Forward P/E | -75.83 |
| Beta | 0.92 | Short Ratio | 0.55 | Inst. Own | 24.86% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 5.89 | 200-d Avg | 7.11 | 1yr Est | 10.00 |
DERM News
Journey Medical (NASDAQ:DERM) reported quarterly losses of $(0.08) per share which met the analyst c
HC Wainwright & Co. analyst Brandon Folkes reiterates Journey Medical (NASDAQ:DERM) with a Bu
Journey Medical (NASDAQ:DERM) reported quarterly losses of $(0.04) per share which beat the analyst
3,750,000 SHARES OF COMMON STOCKWe have entered into an At Market Issuance Sales Agreement (the "
Journey Medical (NASDAQ:DERM) reported quarterly losses of $(0.09) per share which missed the analys
FDA-approved Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate rele
HC Wainwright & Co. analyst Brandon Folkes initiates coverage on Journey Medical (NASDAQ:DERM
Lake Street analyst Thomas Flaten maintains Journey Medical (NASDAQ:DERM) with a Buy and raises t
Shares of Sapiens International Corporation NV (NASDAQ:SPNS) rose sharply in pre-market trading afte
Journey Medical (NASDAQ:DERM) reported quarterly losses of $(0.16) per share which missed the analys
B. Riley Securities analyst Kalpit Patel maintains Journey Medical (NASDAQ:DERM) with a Buy and r
Payer coverage for Emrosi™ now available for 65% of commercial lives, up from 29% in May 2025Expandi
Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or the "Company", "
Journey Medical (NASDAQ:DERM) reported quarterly losses of $(0.18) per share which beat the analyst
DFD-29 (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg
Journey Medical (NASDAQ:DERM) reported quarterly losses of $(0.12) per share which beat the analyst
Journey Medical (NASDAQ:DERM) shares are trading higher Monday after the company announced the U.S.
Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical"), a commercial-stage pharmaceut
Poster Presented on Dermal and Systemic Pharmacokinetics of Oral DFD-29 (Minocycline Hydrochloride M
Lake Street analyst Thomas Flaten initiates coverage on Journey Medical (NASDAQ:DERM) with a Buy
Rodman & Renshaw initiates coverage on Journey Medical (NASDAQ:DERM) with a Buy rating and ann
Journey Medical (NASDAQ:DERM) reported quarterly losses of $(0.17) per share which missed the analys
Roth MKM analyst Jason Wittes reinstates Journey Medical (NASDAQ:DERM) with a Buy and announces $
Journey Medical (NASDAQ:DERM) reported quarterly losses of $(0.53) per share which missed the analys
Journey Medical Corporation ("Journey Medical" or "the Company") (NASDAQ:DERM), a co
The Dow Jones index closed higher by over 475 points on Wednesday. When insiders purchase or sell sh
Shares of Westport Fuel Systems Inc. (NASDAQ: WPRT) fell sharply during Tuesday’s session after pos
Journey Medical (NASDAQ:DERM) reported quarterly earnings of $0.03 per share which beat the analyst